This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, J. Articles by Ricardo, S. D. Search for Related Content PubMed PubMed Citation Articles by Li, J. Articles by Ricardo, S. D.

(American Journal of Pathology. 2006;169:1527-1540.)
© 2006 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2006.060169

Inhibition of p38 Mitogen-Activated Protein Kinase and Transforming Growth Factor-ß1/Smad Signaling Pathways Modulates the Development of Fibrosis in Adriamycin-Induced Nephropathy

Jinhua Li^*, Naomi Vittoria Campanale^*, Rong Jiao Liang^*, James Antony Deane^*, John Frederick Bertram and Sharon Denise Ricardo^*

From Monash Immunology and Stem Cell Laboratories^* and the Department of Anatomy and Cell Biology, Monash University, Victoria, Australia

Inflammation and fibrogenesis are the two determinants of the progression of renal fibrosis, the common pathway leading to end-stage renal disease. The p38 mitogen-activated protein kinase (MAPK) and transforming growth factor (TGF)-ß1/Smad signaling pathways play critical roles in inflammation and fibrogenesis, respectively. The present study examined the beneficial renoprotective effect of combination therapy using the p38 MAPK pathway inhibitor (SB203580) and a TGF-ß receptor I (ALK5) inhibitor (ALK5I) in a mouse model of adriamycin (ADR) nephrosis. The p38 MAPK and TGF-ß1/Smad2 signaling pathways were activated in ADR-induced nephropathy in a sequential time course manner. Two weeks after ADR injection, the combined administration of SB203580 (1 mg/kg/24 hours) and ALK5I (1 mg/kg/24 hours) markedly reduced p38 MAPK and Smad2 activities. Moreover, the co-administration of SB203580 and ALK5I to ADR-injected mice resulted in a down-regulation of total and active TGF-ß1 production, reduced myofibroblast accumulation, and decreased expression of collagen type IV and fibronectin. In these mice, retardation in the development of glomerulosclerosis and interstitial fibrosis was observed. In conclusion, although p38 MAPK and TGF-ß1/Smad signaling pathways are distinct they coordinate the progression of renal fibrosis in ADR nephrosis. The co-administration of a p38 MAPK inhibitor and an ALK5 inhibitor may have potential applications in the treatment of renal fibrosis.

This article has been cited by other articles:

				K. Van Beneden, L. A. van Grunsven, C. Geers, M. Pauwels, A. Desmouliere, D. Verbeelen, A. Geerts, and C. Van den Branden CRBP-I in the renal tubulointerstitial compartment of healthy rats and rats with renal fibrosis Nephrol. Dial. Transplant., June 4, 2008; (2008) gfn290v2. [Abstract] [Full Text] [PDF]

				M. Nishida, Y. Okumura, H. Sato, and K. Hamaoka Delayed inhibition of p38 mitogen-activated protein kinase ameliorates renal fibrosis in obstructive nephropathy Nephrol. Dial. Transplant., May 30, 2008; (2008) gfn309v1. [Abstract] [Full Text] [PDF]

				P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407. [Full Text] [PDF]

				J. Li, J. A. Deane, N. V. Campanale, J. F. Bertram, and S. D. Ricardo The Contribution of Bone Marrow-Derived Cells to the Development of Renal Interstitial Fibrosis Stem Cells, March 1, 2007; 25(3): 697 - 706. [Abstract] [Full Text] [PDF]